Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells

Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells

Chimeric-antigen-receptor (CAR)-T-cell therapy is already widely used to treat patients who are relapsed or refractory to chemotherapy, antibodies, or stem-cell transplantation. Multiple myeloma still constitutes an incurable disease. CAR-T-cell therapy that targets BCMA (B-cell maturation antigen)...

Full description

Bibliographic Details
Main Authors: Avinoam Reichman, Alexander Kunz, Jara J. Joedicke, Uta E. Höpken, Anna Keib, Brigitte Neuber, David Sedloev, Lei Wang, Genqiao Jiang, Angela Hückelhoven-Krauss, Franziska Eberhardt, Carsten Müller-Tidow, Martin Wermke, Armin Rehm, Michael Schmitt, Anita Schmitt
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:International Journal of Molecular Sciences
Subjects:
BCMA-CAR
polymerase chain reaction
detection reagent
flow cytometry
Online Access:https://www.mdpi.com/1422-0067/23/2/903

Internet

https://www.mdpi.com/1422-0067/23/2/903

Similar Items